Humacyte (HUMA) Fundamental Analysis: Revenue, Earnings & Valuation

4.57 / 10

Netural

Fundamentals are mixed (4.6/10). Revenue‑MV, Cash‑MV and Asset‑MV are positive, and YoY revenue growth is strong at 78%. However, fixed‑asset turnover, income‑tax ratio and gross‑margin are weak, limiting overall strength.

Analysis Checks(6/10)

Revenue-MV

Value-4.14

Score2/3

Weight38.38%

1M Return8.45%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight6.09%

1M Return1.54%

Inventory turnover ratio

Value0.07

Score2/3

Weight-4.40%

1M Return-1.21%

Gross profit margin (%)

Value60.53

Score0/3

Weight-22.89%

1M Return-7.24%

PB-ROE

Value1.89

Score0/3

Weight15.74%

1M Return3.23%

Income tax / Total profit (%)

Value-5.45

Score1/3

Weight-1.80%

1M Return-0.50%

Fixed assets turnover ratio

Value0.07

Score1/3

Weight-4.36%

1M Return-1.24%

Cost of sales ratio (%)

Value39.47

Score2/3

Weight-15.03%

1M Return-4.42%

Asset-MV

Value-0.49

Score2/3

Weight60.49%

1M Return12.22%

Cash-MV

Value-0.09

Score2/3

Weight27.79%

1M Return5.94%

Is HUMA undervalued or overvalued?

HUMA scores 4.57/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, 0.00% net margin, -3.61 P/E ratio, 47.37 P/B ratio, and 79.37% earnings growth, these metrics solidify its Netural investment rating.